Citius Pharmaceuticals (CTXR) Short Interest Ratio & Short Volume $1.28 -0.02 (-1.54%) Closing price 04:00 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Citius Pharmaceuticals Short Interest DataCitius Pharmaceuticals (CTXR) has a short interest of 1.12 million shares, representing 10.64% of the float (the number of shares available for trading by the public). This marks a 15.50% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 1.22 million shares to cover all short positions.Current Short Interest1,120,000 sharesPrevious Short Interest969,700 sharesChange Vs. Previous Month+15.50%Dollar Volume Sold Short$1.83 millionShort Interest Ratio0.4 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares10,634,000 sharesFloat Size10,530,000 sharesShort Percent of Float10.64%Today's Trading Volume226,538 sharesAverage Trading Volume1,220,332 sharesToday's Volume Vs. Average19% Short Selling Citius Pharmaceuticals? Sign up to receive the latest short interest report for Citius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCTXR Short Interest Over TimeCTXR Days to Cover Over TimeCTXR Percentage of Float Shorted Over Time Citius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20251,120,000 shares $1.83 million +15.5%10.6%0.4 $1.63 6/30/2025969,700 shares $1.54 million -28.2%9.2%0.4 $1.59 6/15/20251,350,000 shares $1.18 million +103.1%12.8%0.6 $0.87 5/31/2025664,600 shares $459.50 thousand +10.1%6.9%0.3 $0.69 5/15/2025603,400 shares $499.55 thousand -10.0%6.2%2.1 $0.83 4/30/2025670,600 shares $513.01 thousand -11.3%7.2%2.2 $0.77 4/15/2025755,900 shares $755.90 thousand +11.0%8.6%2.6 $1.00 3/31/2025681,200 shares $1.01 million +31.6%7.7%2.3 $1.49 3/15/2025517,600 shares $776.40 thousand -5.4%6.4%3.7 $1.50 2/28/2025547,000 shares $902.55 thousand +1.3%6.8%3.6 $1.65 Get the Latest News and Ratings for CTXR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/2025540,100 shares $1.45 million +5.1%6.7%1.8 $2.69 1/31/2025513,900 shares $1.38 million -12.5%6.4%1.8 $2.69 1/15/2025587,000 shares $2.00 million -1.4%7.3%2.2 $3.40 12/31/2024595,300 shares $2.38 million +13.6%7.5%2.3 $4.00 12/15/2024523,900 shares $1.46 million -13.2%7.3%2.3 $2.79 11/30/2024603,700 shares $2.00 million +12.2%8.4%2.8 $3.32 11/15/2024537,900 shares $2.69 million -95.4%7.5%2.8 $5.00 10/31/202411,790,000 shares $4.39 million -5.1%N/A10.5 $0.37 10/15/202412,420,000 shares $4.65 million -2.7%N/A8.9 $0.37 9/30/202412,770,000 shares $6.39 million +1.9%N/A7.2 $0.50 9/15/202412,530,000 shares $6.51 million -6.4%N/A5.8 $0.52 8/31/202413,390,000 shares $7.63 million +9.0%N/A6.3 $0.57 8/15/202412,280,000 shares $7.20 million -16.1%N/A5.5 $0.59 7/31/202414,630,000 shares $13.24 million +21.9%N/A5.8 $0.91 7/15/202412,000,000 shares $9.18 million -15.2%N/A5.4 $0.77 6/30/202414,150,000 shares $8.26 million -8.5%N/A7.1 $0.58 6/15/202415,460,000 shares $9.67 million -2.8%N/A9.9 $0.63 5/31/202415,910,000 shares $11.10 million +9.9%N/A10.6 $0.70 5/15/202414,480,000 shares $9.05 million +0.4%N/A10.5 $0.62 4/30/202414,430,000 shares $10.77 million +9.4%N/A15.6 $0.75 4/15/202413,190,000 shares $10.09 million +6.1%N/A15.5 $0.77 3/31/202412,430,000 shares $11.15 million +2.1%N/A16.9 $0.90 3/15/202412,180,000 shares $8.97 million +2.7%N/A18.6 $0.74 2/29/202411,860,000 shares $9.11 million +2.4%N/A18.9 $0.77 2/15/202411,580,000 shares $9.75 million -0.3%N/A18.5 $0.84 1/31/202411,610,000 shares $7.21 million -16.7%N/A20.2 $0.62 1/15/202413,940,000 shares $10.46 million -4.7%N/A23.6 $0.75 12/31/202314,620,000 shares $11.06 million +8.6%N/A26.2 $0.76 12/15/202313,460,000 shares $10.73 million -15.0%N/A25.1 $0.80 11/30/202315,830,000 shares $12.20 million -1.3%N/A25.1 $0.77Washington Thinks They Own Your Bank Account (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 11/15/202316,030,000 shares $12.31 million -5.1%N/A25.1 $0.77 10/31/202316,890,000 shares $12.71 million -1.9%N/A23.3 $0.75 10/15/202317,210,000 shares $12.00 million -7.2%N/A17.3 $0.70 9/30/202318,540,000 shares $12.69 million -4.5%N/A18 $0.68 9/15/202319,420,000 shares $14.74 million -1.1%N/A15.9 $0.76 8/31/202319,640,000 shares $17.92 million -1.1%N/A13.3 $0.91 8/15/202319,850,000 shares $17.10 million -4.6%N/A12.7 $0.86 7/31/202320,800,000 shares $20.59 million +2.0%N/A10.8 $0.99 7/15/202320,390,000 shares $24.26 million +8.7%N/A11 $1.19 6/30/202318,760,000 shares $22.51 million +27.9%N/A9.9 $1.20 6/15/202314,670,000 shares $18.48 million +6.6%N/A8.2 $1.26 5/31/202313,760,000 shares $15.96 million +13.4%N/A9.5 $1.16 5/15/202312,130,000 shares $15.53 million -10.8%N/A8.9 $1.28 4/30/202313,600,000 shares $19.72 million +6.7%N/A14.3 $1.45 4/15/202312,750,000 shares $20.91 million +6.5%9.5%14 $1.64 3/31/202311,970,000 shares $14.00 million +4.5%8.9%13.5 $1.17 3/15/202311,450,000 shares $11.79 million +1.5%8.6%13.1 $1.03 2/28/202311,280,000 shares $12.97 million +2.8%8.4%13.6 $1.15 2/15/202310,970,000 shares $13.49 million -5.4%8.2%13.5 $1.23 1/31/202311,600,000 shares $16.12 million +6.6%8.7%14.9 $1.39 1/15/202310,880,000 shares $12.19 million -0.7%8.1%15.3 $1.12 12/30/202210,960,000 shares $8.66 million -3.4%8.2%22 $0.79 12/15/202211,340,000 shares $12.81 million -0.4%N/A23.1 $1.13 11/30/202211,390,000 shares $13.33 million +4.5%N/A23.2 $1.17 11/15/202210,900,000 shares $11.66 million +1.3%N/A22.2 $1.07 10/31/202210,760,000 shares $11.62 million -3.0%N/A19.2 $1.08 10/15/202211,090,000 shares $11.98 million -0.1%N/A19.5 $1.08 9/30/202211,100,000 shares $13.43 million +6.3%N/A17.8 $1.21 9/15/202210,440,000 shares $12.84 million +3.6%N/A12.7 $1.23 8/31/202210,080,000 shares $12.40 million +2.0%N/A11.1 $1.23 8/15/20229,880,000 shares $12.55 million -0.7%N/A9.1 $1.27 7/31/20229,950,000 shares $8.89 million -4.8%N/A7.8 $0.89 7/15/202210,450,000 shares $9.54 million +1.1%N/A6.6 $0.91 6/30/202210,340,000 shares $9.51 million -29.1%N/A5.2 $0.92 6/15/202214,590,000 shares $13.92 million -2.7%N/A7.1 $0.95 5/31/202214,990,000 shares $14.09 million +7.2%11.2%7.9 $0.94 5/15/202213,990,000 shares $12.52 million +5.7%10.5%7.6 $0.90 4/30/202213,230,000 shares $13.36 million +25.1%9.9%7.1 $1.01 4/15/202210,580,000 shares $16.40 million +13.6%7.9%6.3 $1.55 3/31/20229,310,000 shares $16.66 million +2.4%7.0%6.2 $1.79 3/15/20229,090,000 shares $14.36 million +1.8%6.8%6.9 $1.58 2/28/20228,930,000 shares $13.75 million -11.2%6.7%6.2 $1.54 2/15/202210,060,000 shares $16.40 million -6.1%7.5%6.5 $1.63 1/31/202210,710,000 shares $16.17 million -5.3%8.0%6.7 $1.51 1/15/202211,310,000 shares $17.30 million -7.0%8.5%6.7 $1.53 12/31/202112,160,000 shares $18.73 million -7.3%9.1%6.6 $1.54 12/15/202113,110,000 shares $22.29 million +2.5%9.8%6.7 $1.70 11/30/202112,790,000 shares $21.62 million -5.0%9.6%6.2 $1.69 11/15/202113,460,000 shares $24.36 million -7.0%10.1%5.6 $1.81 10/29/202114,470,000 shares $27.06 million +2.1%10.8%5.9 $1.87Washington Thinks They Own Your Bank Account (Ad)What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.Get your free guide now by clicking here >> 10/15/202114,170,000 shares $29.62 million -2.0%10.6%5.3 $2.09 9/30/202114,460,000 shares $29.35 million +0.4%10.8%4.9 $2.03 9/15/202114,410,000 shares $29.25 million +11.2%10.8%2.6 $2.03 8/31/202112,960,000 shares $29.16 million -5.4%9.8%1.6 $2.25 8/13/202113,700,000 shares $24.80 million -6.0%10.3%1.6 $1.81 7/30/202114,570,000 shares $27.54 million -13.9%11.8%1.7 $1.89 7/15/202116,920,000 shares $32.49 million -20.9%13.7%1.7 $1.92 6/30/202121,400,000 shares $74.47 million +40.4%17.4%2.1 $3.48 6/15/202115,240,000 shares $49.23 million -3.7%12.4%2 $3.23 5/28/202115,820,000 shares $36.07 million +8.6%12.9%2.5 $2.28 5/14/202114,570,000 shares $27.54 million +24.3%N/A1.7 $1.89 4/30/202111,720,000 shares $24.73 million -10.4%N/A0.8 $2.11 4/15/202113,080,000 shares $23.54 million +18.6%N/A0.9 $1.80 3/31/202111,030,000 shares $20.41 million +51.3%N/A0.8 $1.85 3/15/20217,290,000 shares $13.92 million -27.9%N/A0.6 $1.91 2/26/202110,110,000 shares $20.83 million +261.1%N/A0.9 $2.06 2/12/20212,800,000 shares $3.81 million +15.7%N/A0.3 $1.36 1/29/20212,420,000 shares $2.90 million +112.3%N/A1.6 $1.20 1/15/20211,140,000 shares $1.30 million -9.5%N/A1.4 $1.14 12/31/20201,260,000 shares $1.31 million -23.6%N/A1.8 $1.04 12/15/20201,650,000 shares $1.77 million +71.8%N/A2.2 $1.07 11/30/2020960,600 shares $947.82 thousand -20.0%N/A1.2 $0.99 11/15/20201,200,000 shares $1.15 million -9.1%N/A1.6 $0.95 10/30/20201,320,000 shares $1.33 million +6.5%N/A1.6 $1.01 10/15/20201,240,000 shares $1.33 million +53.3%N/A1.1 $1.07 9/30/2020809,100 shares $841.46 thousand +15.4%N/A0.6 $1.04 9/15/2020701,200 shares $743.27 thousand -8.9%N/A0.2 $1.06 8/31/2020769,400 shares $715.54 thousand +4.6%N/A0.3 $0.93 8/14/2020735,600 shares $787.09 thousand -59.8%N/A0.2 $1.07 CTXR Short Interest - Frequently Asked Questions What is Citius Pharmaceuticals' current short interest? Short interest is the volume of Citius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 1,120,000 shares of CTXR short. 10.64% of Citius Pharmaceuticals' shares are currently sold short. Learn More on Citius Pharmaceuticals' current short interest. What is a good short interest percentage for Citius Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.64% of Citius Pharmaceuticals' floating shares are currently sold short. Is Citius Pharmaceuticals' short interest increasing or decreasing? Citius Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,120,000 shares, an increase of 15.5% from the previous total of 969,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Citius Pharmaceuticals' float size? Citius Pharmaceuticals currently has issued a total of 10,630,000 shares. Some of Citius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Citius Pharmaceuticals currently has a public float of 10,530,000 shares. How does Citius Pharmaceuticals' short interest compare to its competitors? 10.64% of Citius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Citius Pharmaceuticals: Werewolf Therapeutics, Inc. (3.14%), Precision BioSciences, Inc. (13.33%), Unicycive Therapeutics, Inc. (12.91%), ABVC BioPharma, Inc. (3.64%), PyroGenesis Canada Inc. (0.07%), PDS Biotechnology Corporation (5.34%), MiNK Therapeutics, Inc. (25.32%), CEL-SCI Co. (22.85%), vTv Therapeutics Inc. (0.98%), Exicure, Inc. (6.16%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Citius Pharmaceuticals stock? Short selling CTXR is an investing strategy that aims to generate trading profit from Citius Pharmaceuticals as its price is falling. CTXR shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Citius Pharmaceuticals? A short squeeze for Citius Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CTXR, which in turn drives the price of the stock up even further. How often is Citius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CTXR, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies Werewolf Therapeutics Short Interest Data Precision BioSciences Short Interest Data Unicycive Therapeutics Short Interest Data ABVC BioPharma Short Interest Data PyroGenesis Canada Short Interest Data PDS Biotechnology Short Interest Data MiNK Therapeutics Short Interest Data CEL-SCI Short Interest Data vTv Therapeutics Short Interest Data Exicure Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CTXR) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.